Peptide
Retinalamin
SaveA polypeptide extract from bovine retinal tissue, approved in Russia for diabetic retinopathy and other retinal degenerative conditions.
Quick verdict
Approved in Russia with local clinical data. Not recognized by Western regulators. Evidence quality is limited to Russian publications.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Russian clinical studies report improved visual function in diabetic retinopathy and age-related macular degeneration. No international trials or replication.
Benefits
- Approved in Russia for retinal degenerative conditions
- Some clinical data for diabetic retinopathy symptom improvement
Dosage notes
Russian protocols: 5 mg parabulbar or IM injection daily for 10 days.
Side effects
- Injection-site reactions
- Allergic reactions rare
- Eye irritation with periocular injection
Who should be cautious
Animal-derived biological. Not approved outside Russia/CIS. Requires periocular or IM injection.
What this page cannot tell you
Evidence base is confined to Russian literature. Methodological quality is variable.
Write a review
Sign in to write a review.